Holen Sie sich die Stockscreener-App
16.74
4.40%
-0.77
Handel nachbörslich:
16.40
-0.34
-2.03%
Schlusskurs vom Vortag:
$17.51
Offen:
$17
24-Stunden-Volumen:
340.89K
Relative Volume:
0.67
Marktkapitalisierung:
$313.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.38%
1M Leistung:
+9.84%
6M Leistung:
-23.02%
1J Leistung:
-60.02%
1-Tages-Spanne:
$16.35
$17.50
1-Wochen-Bereich:
$16.35
$26.00
52-Wochen-Spanne:
$13.70
$61.07
Tectonic Therapeutic Inc Stock (TECX) Company Profile
Firmenname
Tectonic Therapeutic Inc
Sektor
Branche
Telefon
(339) 666-3320
Adresse
490 ARSENAL WAY, WATERTOWN
Vergleichen Sie TECX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECX
Tectonic Therapeutic Inc
|
16.74 | 327.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tectonic Therapeutic Inc Stock (TECX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-21 | Eingeleitet | Mizuho | Outperform |
| 2024-11-20 | Eingeleitet | Raymond James | Outperform |
| 2024-08-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-26 | Eingeleitet | Piper Sandler | Overweight |
| 2024-06-24 | Eingeleitet | TD Cowen | Buy |
| 2023-12-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-01-05 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-07-16 | Eingeleitet | Wedbush | Outperform |
| 2018-07-16 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Tectonic Therapeutic Inc Aktie (TECX) Neueste Nachrichten
Price action breakdown for Tectonic Therapeutic Inc.July 2025 Levels & Safe Capital Investment Plans - newser.com
Chart based analysis of Tectonic Therapeutic Inc. trendsMarket Movers & Safe Entry Point Alerts - newser.com
Tools to monitor Tectonic Therapeutic Inc. recovery probabilityQuarterly Earnings Summary & Detailed Earnings Play Strategies - newser.com
How high can Tectonic Therapeutic Inc. stock go2025 EndofYear Setup & Low Risk High Reward Ideas - newser.com
What institutional flow reveals about Tectonic Therapeutic Inc.Earnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
It is Poised to be a Bull Market for Tectonic Therapeutic Inc (TECX) - setenews.com
Tectonic Therapeutic Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Is Tectonic Therapeutic Inc. meeting your algorithmic filter criteriaMarket Risk Report & Weekly High Return Stock Opportunities - newser.com
How to track smart money flows in Tectonic Therapeutic Inc.Earnings Miss & Expert Verified Movement Alerts - newser.com
Can Tectonic Therapeutic Inc. stock sustain market leadershipWeekly Stock Recap & Weekly Setup with ROI Potential - newser.com
What data driven models say about Tectonic Therapeutic Inc.’s futureJuly 2025 Short Interest & Verified High Yield Trade Plans - newser.com
Is Tectonic Therapeutic Inc. stock attractive for retirement portfoliosJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
Truist Financial Sticks to Its Buy Rating for Tectonic Therapeutic (TECX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Is Tectonic Therapeutic Inc. forming a reversal patternQuarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Tectonic Therapeutic (TECX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
What recovery options are there for Tectonic Therapeutic Inc.July 2025 Setups & Entry and Exit Point Strategies - newser.com
Transcript : Tectonic Therapeutic, Inc.Special Call - MarketScreener
Can Tectonic Therapeutic Inc. stock deliver consistent earnings growth2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
Tectonic Therapeutics stock maintains Outperform rating at Oppenheimer By Investing.com - Investing.com Nigeria
Tectonic Therapeutic Reports Positive Phase 1b Trial Results - TipRanks
Tectonic Therapeutics stock maintains Outperform rating at Oppenheimer - Investing.com
Tectonic Therapeutic, Inc. Announces Positive Results from TX45 Phase 1b Part B Trial - TradingView
Why Tectonic Therapeutic Stock Soared 30% After-Hours Today - Asianet Newsable
Tectonic surges on phase 1b data for pulmonary hypertension asset - Seeking Alpha
Tectonic Therapeutic stock soars after positive Phase 1b data for heart failure drug - Investing.com Canada
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - The Manila Times
Tectonic (NASDAQ: TECX) reports -29.2% PCWP, +17.3% CO with TX45 in PH‑HFrEF Phase 1b - Stock Titan
Finanzdaten der Tectonic Therapeutic Inc-Aktie (TECX)
Es liegen keine Finanzdaten für Tectonic Therapeutic Inc (TECX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):